These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24237037)

  • 41. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?
    Schütz E; Gummert J; Mohr FW; Armstrong VW; Oellerich M
    Ther Drug Monit; 1996 Jun; 18(3):228-33. PubMed ID: 8738760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological monitoring of azathioprine therapy.
    Reuther LO; Sonne J; Larsen NE; Larsen B; Christensen S; Rasmussen SN; Tofteng F; Haaber A; Johansen N; Kjeldsen J; Schmiegelow K
    Scand J Gastroenterol; 2003 Sep; 38(9):972-7. PubMed ID: 14531535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
    Yip JS; Woodward M; Abreu MT; Sparrow MP
    Inflamm Bowel Dis; 2008 Apr; 14(4):514-8. PubMed ID: 18088072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Prefontaine E; Sutherland LR; Macdonald JK; Cepoiu M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD000067. PubMed ID: 19160175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
    Reinshagen M; Schütz E; Armstrong VW; Behrens C; von Tirpitz C; Stallmach A; Herfarth H; Stein J; Bias P; Adler G; Shipkova M; Kruis W; Oellerich M; von Ahsen N
    Clin Chem; 2007 Jul; 53(7):1306-14. PubMed ID: 17495015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
    Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A
    BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    Hisamatsu T; Matsumoto T; Watanabe K; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2019 Sep; 13(9):1097-1104. PubMed ID: 30753377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
    Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease.
    Feng R; Guo J; Zhang SH; Qiu Y; Chen BL; He Y; Zeng ZR; Ben-Horin S; Chen MH; Mao R
    J Gastroenterol Hepatol; 2019 Apr; 34(4):679-685. PubMed ID: 30175864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.
    Qian X; Wang T; Shen J; Ran Z
    Medicine (Baltimore); 2018 Aug; 97(34):e11814. PubMed ID: 30142769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 6-thioguanine--efficacy and safety in chronic active Crohn's disease.
    Herrlinger KR; Kreisel W; Schwab M; Schoelmerich J; Fleig WE; Ruhl A; Reinshagen M; Deibert P; Fellermann K; Greinwald R; Stange EF
    Aliment Pharmacol Ther; 2003 Feb; 17(4):503-8. PubMed ID: 12622758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standard-dose versus low-dose azathioprine in the treatment of Crohn's disease: A prospective randomized study.
    Zhang Y; Xia JJ; Xiao P; Zhao Y; Ye LN; Li XL; Lin ZW; Xu ZJ; Huang YB; Wang MY; Qian JM; Hu PJ; Cao Q
    J Dig Dis; 2016 Nov; 17(11):747-755. PubMed ID: 27653444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary: Individual vs. weight-based dosing of azathioprine in Crohn's disease.
    Fraser AG
    Aliment Pharmacol Ther; 2014 Feb; 39(4):438-9. PubMed ID: 24447314
    [No Abstract]   [Full Text] [Related]  

  • 55. [How should azathioprine be dosed in Crohn's disease? a novel strategy of maximum dose-titration based on the lower limit of leukocyte count and tolerability].
    Lim CS; Moon W; Park SJ; Park MI; Choi JM; Yoo JH; Kim JB; Lee JS
    Korean J Gastroenterol; 2013 Aug; 62(2):111-6. PubMed ID: 23981945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.
    Ferrante M; Papamichael K; Duricova D; D'Haens G; Vermeire S; Archavlis E; Rutgeerts P; Bortlik M; Mantzaris G; Van Assche G;
    J Crohns Colitis; 2015 Aug; 9(8):617-24. PubMed ID: 25926532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study.
    Benmassaoud A; Xie X; AlYafi M; Theoret Y; Bitton A; Afif W; Bessissow T
    Can J Gastroenterol Hepatol; 2016; 2016():1034834. PubMed ID: 27446822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Prefontaine E; Macdonald JK; Sutherland LR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD000545. PubMed ID: 19821270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
    Panés J; López-Sanromán A; Bermejo F; García-Sánchez V; Esteve M; Torres Y; Domènech E; Piqueras M; Gomez-García M; Gutiérrez A; Taxonera C; Sans M;
    Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Prefontaine E; Macdonald JK; Sutherland LR
    Cochrane Database Syst Rev; 2010 Jun; (6):CD000545. PubMed ID: 20556747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.